TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00941798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QMF149 Twisthaler®
Description: Once daily via multi-dose dry-powder inhaler

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone Twisthaler®
Description: Once daily via multi-dose dry-powder inhaler
Study: NCT04453423

Intervention type: DRUG
Group type: OTHER
Intervention: Anlotinib + Pemetrexed+Carboplatin
Description: Anlotinib: 12mg, QD, PO, d1-14, 21 days per cycle~Carboplatin: AUC 5 on day 1 of 21 days per cycle~Pemetrexed: 500mg/m2 iv on day 1 of 21 days per cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500mg/m2 iv on day 1 of 21 days per cycle(maintenance phase)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib + Pemetrexed
Description: Anlotinib:12mg, QD, PO, d1-14, 21 days per cycle(maintenance phase)~Pemetrexed:500mg/m2 iv on day 1 of 21 days per cycle(maintenance phase)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: 12mg, QD, PO, d1-14, 21 days per cycle(maintenance phase)
Study: NCT03547492

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teaching Talking
Description: Written packet including 8 lessons: What's My Corrected Age, Watch Me Learn (language milestones in the 1st year of life), Reading Aloud, Sing-a-long: Sleepy Songs, Sing-a-long: Alert Songs, Copying First Sounds, Playing Games, Talk to Your Baby.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LENA recordings-language
Description: LENA a special recording device. It records for 16 hours inside a specially designed infant vest. The recording is analyzed by a computer that generates an output of total number of adult words, infant vocalizations and conversational turns during the recording period. 4 LENA recordings are obtained: baseline, after reviewing Teaching Talking and linguistic feedback of first recording, 4 and 12 months of age. Participants are mailed feedback of their 2nd, 4 and 12 month recordings.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: LENA recordings-motor
Description: LENA a special recording device. It records for 16 hours inside a specially designed infant vest. The recording is analyzed by a computer that generates an output of total number of adult words, infant vocalizations and conversational turns during the recording period. 4 LENA recordings are obtained: baseline, 2nd, 4 and 12 months of age. Participants are mailed feedback on recordings after completing study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mastering Movement
Description: A written curriculum containing 5 lessons adopted from Beautiful Beginnings: What's My Corrected Age, Watch Me Move! (review of motor milestones in 1st year), Gentle Stretching and Exercise, Tummy Time, Help Me Learn to...

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mastering Movement
Description: A written curriculum containing 5 lessons adopted from Beautiful Beginnings: What's My Corrected Age, Watch Me Move! (review of motor milestones in 1st year), Gentle Stretching and Exercise, Tummy Time, Help Me Learn to...

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Language text messages
Description: 12 weekly text messages. Each is 1-2 sentences to review concepts of Teaching Talking

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor text messages
Description: 4 text messages sent every 4 weeks. Each is 1-2 sentences reviewing concepts of Mastering Movement

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motor text messages
Description: 4 text messages sent every 4 weeks. Each is 1-2 sentences reviewing concepts of Mastering Movement
Study: NCT01691625

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: concurrent chemoradiotherapy plus DC-CIK immunotherapy
Description: Radiotherapy:Patients will be conducted CT simulation, and three-dimensional conformal radiation therapy (3DCRT) or Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 60-66Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator.~Chemotherapy: Patients will be concurrently administered with irradiation every 4 weeks with PT regimen (cis-platinum of 20 mg/m2/d, d2-5; PTX(paclitaxel)of 80mg/m2/d, d1,d8) for 4 cycles.The chemotherapy will be concurrently given with irradiation.~DC-CIK Immunotherapy:Mononuclear cells were collected aseptically with blood cell separator composition apheresis 3 days before concurrent chemoradiation, and cultured DC-CIK cells for 10 days. Cells were infused back to the patients in 3 times between the Chemoradiation intermittent period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent chemoradiation only
Description: Radiotherapy:Patients will be conducted CT simulation, and three-dimensional conformal radiation therapy (3DCRT) or Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 60-66Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator.~Chemotherapy: Patients will be concurrently administered with irradiation every 4 weeks with PT regimen (cis-platinum of 20 mg/m2/d, d2-5; PTX(paclitaxel)of 80mg/m2/d, d1,d8) for 4 cycles.The chemotherapy will be concurrently given with irradiation.
Study: NCT03960489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Participants will receive single dose of 100 mg azo dye free tablet or mini tablet suspension or solid mini tablet or dye containing tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Participants will receive single dose of 100 mg azo dye free tablet or mini tablet suspension or solid mini tablet or dye containing tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Participants will receive single dose of 100 mg azo dye free tablet or mini tablet suspension or solid mini tablet or dye containing tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Participants will receive single dose of 100 mg azo dye free tablet or mini tablet suspension or solid mini tablet or dye containing tablet.
Study: NCT05514080

Intervention type: OTHER
Group type: OTHER
Intervention: Insulin closed-loop
Description: 41-hour intervention period in which the participants are treated with rapid insulin in the closed-loop system.
Study: NCT03115333

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging
Description: Undergo DSC-MRI
Study: NCT01569659

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lurasidone
Description: 80 mg/day for up to 30 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone
Description: Up to 240 mg/day for up to 30 weeks
Study: NCT02093325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: This will be a Phase III, randomized, double-blind, placebo-controlled clinical trial. Qualified subjects will be randomly assigned to receive either the test treatment or the placebo at 2:1 ratio. Once subjects are randomized, they will be treated with Arm A: Eltrombopag 50 mg/day (n=55) or Arm B: placebo (n=28) once a day for 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This will be a Phase III, randomized, double-blind, placebo-controlled clinical trial. Qualified subjects will be randomly assigned to receive either the test treatment or the placebo at 2:1 ratio. Once subjects are randomized, they will be treated with Arm A: Eltrombopag 50 mg/day (n=55) or Arm B: placebo (n=28) once a day for 7 days.
Study: NCT02165332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1: SAD RO7033877
Description: Single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Part 1: SAD placebo
Description: Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2: Treatment A, RO7033877
Description: Single dose RO7033877 and moxifloxacin placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2: Treatment B, RO7033877
Description: Single dose RO7033877 and moxifloxacin placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2: Treatment C, moxifloxacin
Description: Single dose moxifloxacin and RO7033877 placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2: Treatment D, RO7033877 and moxifloxacin placebo
Description: Single dose moxifloxacin placebo and RO7033877 placebo
Study: NCT02310022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug Omega 3
Description: 4 g (4 capsules) once a day, administered with food

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug Omega-3 Comparator
Description: 4 g (4 capsules) once a day, administered with food
Study: NCT02981901

Intervention type: OTHER
Intervention: Patient with ovarian epithelial cancer
Study: NCT01696448

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CAR-191
Description: Patients will be randomized to the CAR-191 intervention group in a 3:1, CAR0-191:placebo ratio. There will be 30 patients in the CAR-191 treatment group.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be randomised in a 3:1 ratio. There will be 10 patients in the placebo group.
Study: NCT03661502

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VVV
Description: ventilation mode with variable tidal volume is chosen. the average tidal volume is 6 ml/kg and respiratory rate adapted to reach end tidal con between 30 and 50 mmHg

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCV
Description: ventilation mode with constant tidal volume is chosen. the tidal volume is 6 ml/kg and respiratory rate adapted to reach end tidal con between 30 and 50 mmHg
Study: NCT04653441

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Child-Caregiver-Advocacy-Resilience [ChildCARE] intervention
Description: The proposed multimodal Child Caregiver-Advocacy-Resilience intervention (ChildCARE) will include three integrated components: the individual child (peer-group activities), family (caregiver parenting skill training), and the local community (community advocacy).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Child-Caregiver-Advocacy-Resilience [ChildCARE] intervention
Description: The proposed multimodal Child Caregiver-Advocacy-Resilience intervention (ChildCARE) will include three integrated components: the individual child (peer-group activities), family (caregiver parenting skill training), and the local community (community advocacy).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Child-Caregiver-Advocacy-Resilience [ChildCARE] intervention
Description: The proposed multimodal Child Caregiver-Advocacy-Resilience intervention (ChildCARE) will include three integrated components: the individual child (peer-group activities), family (caregiver parenting skill training), and the local community (community advocacy).
Study: NCT01793025

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATAC Therapy
Description: Unselected peripheral blood mononuclear cells given 24-48 hours after induction or consolidation chemotherapy
Study: NCT02228954

Intervention type: PROCEDURE
Intervention: Molecular imaging
Study: NCT05296499

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary exercise test (CPET)
Description: Cardiopulmonary exercise testing using cycle ergonomenter

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary exercise test (CPET)
Description: Cardiopulmonary exercise testing using cycle ergonomenter

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary exercise test (CPET)
Description: Cardiopulmonary exercise testing using cycle ergonomenter

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary exercise test (CPET)
Description: Cardiopulmonary exercise testing using cycle ergonomenter

Intervention type: DIAGNOSTIC_TEST
Intervention: Exercise cardiac MRI
Description: Exercise cardiac MRI using supine cycle, participants exercised to peak workload as determined by CPET

Intervention type: DIAGNOSTIC_TEST
Intervention: Exercise cardiac MRI
Description: Exercise cardiac MRI using supine cycle, participants exercised to peak workload as determined by CPET

Intervention type: DIAGNOSTIC_TEST
Intervention: Exercise cardiac MRI
Description: Exercise cardiac MRI using supine cycle, participants exercised to peak workload as determined by CPET

Intervention type: DIAGNOSTIC_TEST
Intervention: Exercise cardiac MRI
Description: Exercise cardiac MRI using supine cycle, participants exercised to peak workload as determined by CPET

Intervention type: OTHER
Intervention: 6 minute walk test
Description: 6MWT

Intervention type: OTHER
Intervention: 6 minute walk test
Description: 6MWT

Intervention type: OTHER
Intervention: 6 minute walk test
Description: 6MWT

Intervention type: OTHER
Intervention: 6 minute walk test
Description: 6MWT

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood tests
Description: FBC, U\&E, LFTS

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood tests
Description: FBC, U\&E, LFTS

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood tests
Description: FBC, U\&E, LFTS

Intervention type: OTHER
Intervention: Quality of life questionnaires
Description: SF36, EQ5D, VEINES-QoL/Sym

Intervention type: OTHER
Intervention: Quality of life questionnaires
Description: SF36, EQ5D, VEINES-QoL/Sym

Intervention type: OTHER
Intervention: Quality of life questionnaires
Description: SF36, EQ5D, VEINES-QoL/Sym

Intervention type: OTHER
Intervention: Quality of life questionnaires
Description: SF36, EQ5D, VEINES-QoL/Sym

Intervention type: OTHER
Intervention: Repeat baseline assessments
Description: repeat baseline

Intervention type: OTHER
Intervention: Repeat baseline assessments
Description: repeat baseline

Intervention type: OTHER
Intervention: Repeat baseline assessments
Description: repeat baseline

Intervention type: OTHER
Intervention: Repeat baseline assessments
Description: repeat baseline

Intervention type: DIAGNOSTIC_TEST
Intervention: MR venogram
Description: MRI scan of venous system

Intervention type: DIAGNOSTIC_TEST
Intervention: MR venogram
Description: MRI scan of venous system

Intervention type: DIAGNOSTIC_TEST
Intervention: MR venogram
Description: MRI scan of venous system
Study: NCT04248647

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal prehabilitation
Description: This arm will receive a 4-week prehabilitation program consisting of:~Exercise: Participants will receive a 3x/week aerobic and strength training exercise program. They will perform 2 workouts per week at home and attend an in-hospital supervised exercise session once per week.~Nutritional counselling: Participants will meet with a registered dietician who will provide personalized nutritional recommendations and a whey protein supplement, tailored according to participants' self-reported dietary intake and anthropometric measurements.~Psychological support: Participants will receive a 90-minute session at baseline, and weekly in-hospital follow-ups throughout the preoperative period. The sessions will aim to reduce preoperative distress and improve adherence to the exercise program and nutritional recommendations. Psychological support will be delivered by a trained master's student, under the direct supervision of a registered Clinical Psychologist.
Study: NCT02149784

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection of primary tumor
Description: Surgical resection of primary tumor of mCRC patients who were respond to first line chemotherapy'
Study: NCT04654039

Intervention type: OTHER
Intervention: Other: Non intervention
Description: Non intervention
Study: NCT01521962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin
Description: Insulin injection
Study: NCT00426725

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EasyLabour
Description: According to the trial protocol

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: EasyLabour
Description: According to the trial protocol
Study: NCT00946335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: veliparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02843256

Intervention type: DEVICE
Intervention: Isomark Canary
Description: The Isomark Canary will analyze the exhaled air and generate a breath delta value.
Study: NCT01106443

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Thyroidectomy + CLND
Description: Total thyroidectomy includes removing all possible thyroid tissue. Central lymph node dissection is a neck level 6 dissection. This includes removal of all central lymphatics from carotid artery to carotid artery and hyoid to sternum/clavicle.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total thyroidectomy - CLND
Description: Removal of all possible thyroid tissue without dissection of neck level 6.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemi-thyroidectomy + CLND
Description: Removal of one thyroid lobe and ipsilateral central lymph nodes

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemi-thyroidectomy - CLND
Description: Removal of one thyroid lobe only. No lymphatic dissection.
Study: NCT02073461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD1579 2.5%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD1579 5%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Study: NCT01612325

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Holmium-166 polylactic microspheres
Description: Radioembolisation with 600 mg of Holmium-166 microspheres with a patient liver size adjusted activity. The desired whole liver dose is 60 Gy.
Study: NCT00583622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/kg by vein daily over 90 minutes for 2 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: 333 mg/m\^2 by vein over 2 hours for 3 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 300 mg/m\^2 by vein over 2 hours for 1 Day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1,800 mg/m2 by vein over 3 hours for 4 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 50 mg/m\^2 by vein over 15 minutes for 3 Days

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Description: * Stem Cell Removal via apheresis through a central venous catheter (CVC), usually in chest~* Stem Cell Replacement through CVC over about 30-60 minutes, Day 7 of treatment, following study drug regimen
Study: NCT01965938

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RIFL (Rigid and Flexing Laryngoscope)
Description: Patients in the RIFL group will undergo bronchoscopy using the Rigid and Flexing Laryngoscope. Once the carina is visualized with the bronchoscope, the endotracheal tube will be advanced, and the bronchoscope removed.

Intervention type: DEVICE
Group type: OTHER
Intervention: Fiberoptic Bronchoscope
Description: Patients in the control group will undergo bronchoscopy using the flexible fiberoptic bronchoscope. Once the carina is visualized with the bronchoscope, the endotracheal tube will be advanced, and the bronchoscope removed.
Study: NCT04741516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Foquest
Description: The drug being evaluated in this study is controlled release methylphenidate HCl control (Foquest®). Foquest® is a novel formulation of MPH developed by Purdue Pharma (Canada) and is approved in Canada for the treatment of ADHD in patients six years of age and older. Foquest® is the first methylphenidate product approved in Canada with an onset of action within one hour and a duration of action up to and including 16 hours (Wigal et al.2016). Foquest® is an ADHD treatment option for patients who require a rapid onset of action and extended duration of action
Study: NCT00921063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0332334
Description: 250 mg capsule, BID for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0332334
Description: 100 mg capsule, BID for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 0 mg capsule, BID for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alprazolam extended release
Description: 1 mg capsule, BID for 4 weeks
Study: NCT00493077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low immunogenic interferon-beta-1a
Description: dosage and frequency as per Biogen Idec protocol
Study: NCT00674622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prolotherapy
Description: Injection of 15% dextrose with lidocaine at the lateral epicondyle

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline/lidocaine

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline/lidocaine
Study: NCT02484170

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mannitol cream
Description: Apply to area of postherpetic neuralgia pain as needed for pain control. Usual frequency is 2 to 3 times per day.For crossover study, will be applied for 7 days. For observational study, will be applied up to 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mannitol cream
Description: Apply to area of postherpetic neuralgia pain as needed for pain control. Usual frequency is 2 to 3 times per day.For crossover study, will be applied for 7 days. For observational study, will be applied up to 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Apply to area of postherpetic neuralgia pain as needed for pain control.Usual frequency is unknown. For crossover study, will be applied for 7 days. Will not be used after crossover study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Apply to area of postherpetic neuralgia pain as needed for pain control.Usual frequency is unknown. For crossover study, will be applied for 7 days. Will not be used after crossover study
Study: NCT01471639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal ketorolac
Description: 15 mg
Study: NCT03535142

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Description: Roux en y gastric bypass or gastric sleeve operation
Study: NCT03681418

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ultrasound-guided axillary lymph nodes FNAC and\or CNB.
Description: Ultrasound-guided axillary lymph node fine needle aspiration and\\or core needle biopsy of the most suspicious lymph node. If all the lymph nodes appeared similar or normal, the lymph node that is lowest in the axilla will be selected because it is considered to most likely be the sentinel node.